Data Insights

Ustekinumab biosimilar by Formycon for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval

Ustekinumab biosimilar is under clinical development by Formycon and currently in Pre-Registration for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ustekinumab Biosimilar in Plaque Psoriasis (Psoriasis Vulgaris)

Data Insights

Ustekinumab biosimilar by STgen Bio for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval

Ustekinumab biosimilar is under clinical development by STgen Bio and currently in Pre-Registration for Plaque Psoriasis (Psoriasis Vulgaris). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Ustekinumab Biosimilar in Plaque Psoriasis (Psoriasis Vulgaris)

Data Insights

Ustekinumab biosimilar by Celltrion for Ulcerative Colitis: Likelihood of Approval

Ustekinumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Ulcerative Colitis. According to GlobalData, Pre-Registration drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Ustekinumab Biosimilar in Ulcerative Colitis

Data Insights

Ustekinumab biosimilar by Celltrion for Crohn's Disease (Regional Enteritis): Likelihood of Approval

Ustekinumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Crohn's Disease (Regional Enteritis). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ustekinumab Biosimilar in Crohn's Disease (Regional Enteritis)

Data Insights

Ustekinumab biosimilar by Rani Therapeutics for Psoriasis: Likelihood of Approval

Ustekinumab biosimilar is under clinical development by Rani Therapeutics and currently in Phase I for Psoriasis. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ustekinumab Biosimilar in Psoriasis

Data Insights

Ustekinumab biosimilar by Rani Therapeutics for Psoriatic Arthritis: Likelihood of Approval

Ustekinumab biosimilar is under clinical development by Rani Therapeutics and currently in Phase I for Psoriatic Arthritis. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ustekinumab Biosimilar in Psoriatic Arthritis

Data Insights

Ustekinumab biosimilar by Celltrion for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval

Ustekinumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ustekinumab Biosimilar in Plaque Psoriasis (Psoriasis Vulgaris)

Data Insights

Ustekinumab biosimilar by Celltrion for Psoriatic Arthritis: Likelihood of Approval

Ustekinumab biosimilar is under clinical development by Celltrion and currently in Pre-Registration for Psoriatic Arthritis. According to GlobalData, Pre-Registration drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Ustekinumab Biosimilar in Psoriatic Arthritis

Data Insights

Ustekinumab biosimilar by Biocon for Crohn's Disease (Regional Enteritis): Likelihood of Approval

Ustekinumab biosimilar is under clinical development by Biocon and currently in Phase III for Crohn's Disease (Regional Enteritis). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Ustekinumab Biosimilar in Crohn's Disease (Regional Enteritis)